title: Desensitization and renal transplant: plasmapheresis/IVIG standard dose in patients with high immunological risk.
abstract: BACKGROUND
  Patients with high immunological risk have been relegated to the growing waiting list for an immunologically compatible donor. Our objective was to report the experience of a transplant center in desensitization of patients with high immunological risk.
  
  
  METHODS
  We carried out a descriptive and retrospective study. Included were all the renal transplant patients from November 1999 to January 2008 in which we used plasmapheresis and standard dose of intravenous immunoglobulin (IVIG) as desensitization.
  
  
  RESULTS
  Eight patients had history of alloimmunity (positive crossmatch or high panel-reactive antibodies (PRA >30%). Desensitization was accomplished with plasmapheresis and exchange of 1.5 plasma volume. Subsequent to each session we administered a standard dose of IVIG (5 g/dose). Immunosuppression began equal to the first plasmapheresis with calcineurin inhibitor (tacrolimus) plus six patients with mycophenolate mofetil and two patients with sirolimus. In seven cases, negative crossmatches were obtained before the transplantation, except in the eighth case in whom it was not done. Two patients received human antibodies against CD25 (basiliximab, 20 mg/dose). During their evolution, all patients maintained stable graft function.
  
  
  CONCLUSIONS
  According to our experience, renal graft outcome in patients with high immunological risk after an adequate desensitization protocol is similar to that observed in nonsensitized patients, at least during the first year of transplantation.
authors: Servicio de Cirugía de Trasplantes, Instituto Mexicano de Trasplantes, México, D.F., Mexico. khanscrew@hotmail.com
authors: Francisco
authors: F
authors: Flores-Gama
authors: Guillermo Antonio
authors: GA
authors: Mondragón-Ramírez
authors: Tommaso
authors: T
authors: Bochicchio-Riccardelli
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods* / Q000706:statistics & numerical data; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000706:statistics & numerical data; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012086:Reoperation; D012189:Retrospective Studies; D012306:Risk; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab